IGSF11 and glioma: Using the same cohort of patients (TCGA), we assessed the correlation of IgSF11 expression with three critical immune checkpoints, PDL-1 and PD-1 (both known to present high levels of expression in advanced glioma grades) (23–25) and VISTA, which is known as IgSF11 receptor (20).